Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > TSXV:ACST ~ Agrees to acquire Grace Therapeutics !!

<< Previous

Bullboard Posts

Next >>

Comment by markovschrilovoon May 07, 2021 2:42pm

150 Views

Post# 33153894

RE:TSXV:ACST ~ Agrees to acquire Grace Therapeutics !!

https://www.nasdaq.com/market-activity/stocks/acst/historical

Wonderous. Biological Medical Companies is the big business. Good luck to Sadeh P.o.S trying to Gew His Way against

TiffinTech wrote:
TSXV:ACST $47.96M

Simon DrukerMarkets Reportersimon.druker@themarketherald.ca07 May 2021

Acasti Pharma (ACST) has entered into a definitive agreement to acquire emerging biopharmaceutical company Grace Therapeutics Grace Therapeutics is focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases Acasti will acquire Grace’s entire therapeutic pipeline consisting Grace provides Acasti with a pipeline of rare and orphan disease programs, including 3 clinical stage assets that have received FDA Orphan Drug Designation Acasti Pharma is up 25.25 per cent, trading at $0.62 per share at 12:43 pm ET Acasti Pharma (ACST) has entered into a definitive agreement to acquire emerging biopharmaceutical company Grace Therapeutics. Grace Therapeutics is a privately-held company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases. Acasti is expected to acquire Grace’s pipeline of drug candidates addressing critical unmet medical needs with the potential to deliver significant value to patients and providers. The proposed transaction has been approved by the boards of directors of both companies and is supported by Grace shareholders. The transaction remains subject to approval of Acasti stockholders, as well as applicable stock exchanges. It is anticipated that the cash at closing of about C$64 million will be principally used to pursue the clinical development of the first two assets through Phase 3, and further advance earlier pipeline assets into the clinic. In connection with the proposed transaction, Acasti will acquire Grace’s entire therapeutic pipeline consisting of three unique clinical stage and multiple pre-clinical stage assets supported by an intellectual property portfolio consisting of more than 40 granted and pending patents in various jurisdictions worldwide. "We believe that Grace’s assets represent a transformative opportunity for Acasti, as their novel drug delivery technologies used to develop new therapies could improve upon existing compounds with known safety profiles and provide an attractive path to drug development and commercialization. We believe Grace’s product portfolio has the potential to provide better patient solutions with enhanced efficacy, faster onset of action, reduced side effects, convenient delivery, and increased patient compliance. For these and other reasons, we are very excited about the therapeutic potential of Grace’s pipeline, and we believe there could be significant international licensing and marketing opportunities for these assets," said Acasti Chief Executive Officer Jan D’Alvise.